The ADVANCE trial study design1,2
The efficacy of high-dose, low-frequency PLEGRIDY was assessed from the placebo-controlled first year (48 weeks) of a 2-year, randomized, double-blind clinical study, including 1,512 patients with relapsing forms of MS.
- Expanded Disability Status Scale (EDSS) score of 0.0 to 5.0
- ≥2 relapses within last 3 years, with at least 1 within 12 months prior to randomization1
- The trial excluded patients with progressive forms of MS1
Baseline patient characteristics1,3
Study endpoints at 1 year1